GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) » Definitions » Return-on-Tangible-Asset

Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Return-on-Tangible-Asset : -134.42% (As of Jun. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Biohaven Pharmaceutical Holding Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Biohaven Pharmaceutical Holding Co's annualized Net Income for the quarter that ended in Jun. 2022 was $-1,765.5 Mil. Biohaven Pharmaceutical Holding Co's average total tangible assets for the quarter that ended in Jun. 2022 was $1,313.5 Mil. Therefore, Biohaven Pharmaceutical Holding Co's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2022 was -134.42%.

The historical rank and industry rank for Biohaven Pharmaceutical Holding Co's Return-on-Tangible-Asset or its related term are showing as below:

BHVN' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -531.82   Med: -154.57   Max: -84.28
Current: -84.28

During the past 7 years, Biohaven Pharmaceutical Holding Co's highest Return-on-Tangible-Asset was -84.28%. The lowest was -531.82%. And the median was -154.57%.

BHVN's Return-on-Tangible-Asset is not ranked
in the Biotechnology industry.
Industry Median: -40.005 vs BHVN: -84.28

Biohaven Pharmaceutical Holding Co Return-on-Tangible-Asset Historical Data

The historical data trend for Biohaven Pharmaceutical Holding Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Pharmaceutical Holding Co Return-on-Tangible-Asset Chart

Biohaven Pharmaceutical Holding Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Return-on-Tangible-Asset
Get a 7-Day Free Trial -146.28 -110.29 -166.74 -154.57 -101.47

Biohaven Pharmaceutical Holding Co Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -97.21 -73.80 -76.06 -39.85 -134.42

Competitive Comparison of Biohaven Pharmaceutical Holding Co's Return-on-Tangible-Asset

For the Biotechnology subindustry, Biohaven Pharmaceutical Holding Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biohaven Pharmaceutical Holding Co's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biohaven Pharmaceutical Holding Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Biohaven Pharmaceutical Holding Co's Return-on-Tangible-Asset falls into.



Biohaven Pharmaceutical Holding Co Return-on-Tangible-Asset Calculation

Biohaven Pharmaceutical Holding Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2021 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=-846.586/( (647.888+1020.774)/ 2 )
=-846.586/834.331
=-101.47 %

Biohaven Pharmaceutical Holding Co's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2022 )  (Q: Mar. 2022 )(Q: Jun. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2022 )  (Q: Mar. 2022 )(Q: Jun. 2022 )
=-1765.548/( (1315.807+1311.137)/ 2 )
=-1765.548/1313.472
=-134.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2022) net income data.


Biohaven Pharmaceutical Holding Co  (NYSE:BHVN) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Biohaven Pharmaceutical Holding Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Business Description

Traded in Other Exchanges
N/A
Address
C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.
Executives
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
George C. Clark officer: VP, Chief Accounting Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Elyse Stock officer: Chief Medical Officer 215 CHURCH STREET NEW HAVEN CT 06510
James Engelhart officer: Chief Financial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten officer: Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Declan Doogan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John W Childs director, 10 percent owner 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Kishan Mehta director 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Jones William A Jr officer: CCO-Migraine & Common Disease NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Kimberly Gentile officer: VP of Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Robert Berman officer: Chief Medical Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John Tilton officer: Chief Commercial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054

Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Headlines